Clementia Pharmaceuticals Inc.
CMTA
CMTA was delisted on the 17th of April, 2019.
45 hedge funds and large institutions have $353M invested in Clementia Pharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$170M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$35M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.6M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$13.4M |
| 5 |
Janus Henderson Group
London,
|
+$12.4M |
Top Sellers
CMTA Hedge Fund Activity: Q3 2017 in Review
45 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q3 2017, worth a combined $353M.
Buyers outnumbered sellers: 45 funds opened new CMTA positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $170M.
- 45 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $353M of Clementia Pharmaceuticals Inc. stock for Q3 2017.
- 45 funds opened new Clementia Pharmaceuticals Inc. positions in Q3 2017 and 0 closed out, a net change of +45 holders.
- The largest Clementia Pharmaceuticals Inc. buyer in Q3 2017 was OrbiMed, an estimated $170M added.
Based on aggregated 13F filings for Q3 2017.